Primecap Management’s KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) KBIO Stock Holding History

Primecap Management’s Portfolio KBIO Stock Details KBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	–	Sell	-534,885	Closed	-$1.02M	–	278
2015 Q3	$1.02M	Sell	534,885 -6,065	-1%	-$16K	﹤0.01%	269
2015 Q2	$2.08M	Sell	540,950 -3,088	-0.6%	-$13.1K	﹤0.01%	248
2015 Q1	$2.13M	Sell	544,038 -15,425	-3%	-$69.2K	﹤0.01%	246
2014 Q4	$7.74M	Hold	559,463	–	–	0.01%	227
2014 Q3	$6.94M	Hold	559,463	–	–	0.01%	225
2014 Q2	$10.2M	Sell	559,463 -26,971	-5%	-$462K	0.01%	212
2014 Q1	$12.7M	Sell	586,434 -1,063	-0.2%	-$30.8K	0.01%	205
2013 Q4	$20.8M	Sell	587,497 -837	-0.1%	-$28K	0.03%	193
2013 Q3	$21.3M	Buy	588,334 +128,125	+28%	+$5.84M	0.03%	187
2013 Q2	$20.8M	Buy	+460,209	New	+$20.9M	0.03%	184

Other funds holding KBIO

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

California Public Employees Retirement System Sacramento, California $177B AUM 39.86% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Creative Planning Overland Park, Kansas $171B AUM 24.68% 1-Year Est. Return

Primecap Management's KBIO Position: Q4 2015 in Review

Primecap Management sold out of KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) (KBIO) in Q4 2015, closing a stake of 534,885 shares — an estimated $1.02M sold.

Primecap Management first reported a position in KBIO in Q2 2013 and held it in 10 quarters. The position peaked at $21.3M in Q3 2013. 17 funds tracked by Wall St. Rank hold KBIO as of Q4 2015.

Primecap Management reported no remaining KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) position as of Q4 2015 after selling out during the quarter.
Primecap Management sold 534,885 KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) shares in Q4 2015, an estimated $1.02M.
Primecap Management first reported a position in KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) in Q2 2013 and held it in 10 quarters.
Primecap Management's KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) position peaked at $21.3M in Q3 2013.
17 funds tracked by Wall St. Rank held KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) as of Q4 2015.

Based on Primecap Management's 13F filing for Q4 2015, filed 12 Feb 2016.